Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy - Rachel Ham; John Gardner; Adrian Carter; Paul Liknaitzky (Brain and Behavior, 2026)

We Licked the Toads so You Don't Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5-Methoxy-N,N-Dimethyltryptamine. - Homon A; Laramie J; Hayward JJ; Trant JF (ChemMedChem, 2026)

Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice. - Kala K; Bederska-Lojewska D; Lazur J; Gasior K; Maslanka A; Szewczyk A; Sulkowska-Ziaja K; Turek J; Szewczyk B; Pilc A; Muszynska B. (2026)

MDMA and Psilocybin Regulate Oligodendrocyte-Lineage Cell Numbers and Anxiety-Like Behaviors in a Rat Model of Fear - Mehmet Bostancıklıoğlu; Davut Sinan Kaplan; Ramazan Bal; Elif Yiğit; Hasan Ulusal; Ebru Temiz (Biological Psychiatry, 2026)

Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects - Anna Maria Komarczewska; Filip Matusiak; Klaudia Brzoza; Michał Kociński; Patryk Iglewski; Michał Pietrasz (Quality in Sport, 2026)

Regarding “The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses” - Jesper L. Kristensen (Translational Psychiatry, 2026)

The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review - Lukasz Siwek; Marta Nowocien; Barbara Balajewicz; Angelika Samborska; Sara Szukalska; Marta Karczewska; Karolina Lichwala; Kamil Wroblewski; Paulina Wróblewska (Cureus, 2026)

PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial - James Downar; Julie Lapenskie; Koby Anderson; Gaelle Parsons; Nadia Polskaia; Genevieve Lalumiere; Peter G. Lawlor (Palliative Medicine, 2026)

Psilocybin and the Evolutionary Significance of Altered Neural States: Interaction-Based Perspectives Beyond Deterrence Models - Philip Rebensburg (2026)

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION - Łukasz Deska; Cezary Kosmecki; Dawid Głaz; Natalia Kamińska; Wojciech Sołtys; Magdalena Stolarczyk; Maksymilian Głaz; Mateusz Stronczyński; Aleksandra Jagura-Sukiennik; Julia Wawerska (International Journal of Innovative Technologies in Social Science, 2026)

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial - Bruyère Health Research Institute. (ClinicalTrials.gov, 2026)

Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications - Cheng-Teng Ip; Sebastian Olbrich; Mateo de Bardeci; Anna Monn; Andres Ort; John W. Smallridge; Franz Vollenweider (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2026)

The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence - Fernando Mora López; Johynny Solís Solís; Ekaterina Daniela Hernández Baker; Olger Herrera Barboza; David Diaz Polo; Daniela Consumi Cordero (Zenodo (CERN European Organization for Nuclear Research), 2026)

Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure - Marco Banzato; Martina Colognesi; Lorena Lucatello; Stefano Comai; Gianfranco Pasut; Francesca Capolongo; Laura Orian; Lucia Biasutto; Anna Signor; Daniela Gabbia; Paolo L. Manfredi; Sara De Martin; et al. (Journal of Medicinal Chemistry, 2026)

Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience - Jess Kerr-Gaffney; Samuel Myrtle; Famia Askari; Catherine Bird; Nadav Liam Modlin; Allan H. Young; James Rucker (Journal of Psychopharmacology, 2026)

The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression - Rishika Scott; James Smith (Emerging Minds Journal for Student Research, 2026)

Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis - Omer A. Syed; Benjamin Tsang; Sean M. Nestor; Nir Lipsman; Muhammad Ishrat Husain; Fahad Alam; Peter Giacobbe (Neuroscience & Biobehavioral Reviews, 2026)

A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment - NYU Langone Health (ClinicalTrials.gov, 2026)

THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS - Jakub Klepacz; Radosław Swędrak; Marzena Swojnóg; Zuzanna Dobrakowska (International Journal of Innovative Technologies in Social Science, 2026)

Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin - Marija Franka Žuljević; Antonija Mijatović; Renata Orhanović; Glenn Goasdoué; Diana Gujinović (Journal of Clinical Epidemiology, 2026)

Is psilocybin only effective as part of psychotherapy? - Tripdatabase (Zenodo (CERN European Organization for Nuclear Research), 2026)

Does psilocybin help with mental health conditions? - Tripdatabase (Zenodo (CERN European Organization for Nuclear Research), 2026)

The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma - Baylor College of Medicine (ClinicalTrials.gov, 2026)

No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain - Nicholas Gregory; Tyler E. Girard; Akila Ram; Austen B. Casey; RC Malenka; Vivianne L. Tawfik; Boris D. Heifets (Nature Communications, 2026)

Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms - Ana Domi; Erika Lucente; Davide Cadeddu; Niklas Bengtsson; Erik Smedler; Louise Adermark (Neuropharmacology, 2026)

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms - Martina Colognesi; Daniela Gabbia; Anna Signor; Miles Sarill; Lucia Centofanti; Andrea Rinaldi; Luciano Cascione; Sara Nunziata; Marco Banzato; Andrea Mattarei; Giovanna Finzi; Sonia Sonda; et al. (Repository for Publications and Research Data (ETH Zurich), 2026)

Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis - Piotr Olejnik; Katarzyna Kamińska; Krystyna Gołembiowska; Kaja Kasarełło (Pharmacological Reports, 2026)

Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts - Laura Mills; Susan L. Rossell; Sean Carruthers (Journal of Affective Disorders, 2026)

Systematic study of Panaeolus (Agaricales, Galeropsidaceae) sensu lato and psilocybin-producing traits of species from China - Mao-Qiang He; Wen-Qiang Yang; Dorji Phurbu; Fei Liu; Jiaxin Li; Bin Cao; Rui-Lin Zhao (IMA Fungus, 2026)

Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy - Zoe Doyle; Noah Chisamore; Erica Kaczmarek; Danica E. Johnson; Ryan M. Brudner; Geneva Weiglein; Marc G. Blainey; Jordan Bawks; Jeremy Riva-Cambrin; Rickinder Sethi; Roger S. McIntyre; Joshua D. Rosenblat (General Hospital Psychiatry, 2026)

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study - Anthony L. Back; Bonnie A. McGregor; Leslie Lazar Thorn; Kelsey K. Baker; T. Gooley; Mendel Kaelen; Kalin Harvey; John M. Guy; Susanna Myers; Juliana Pérez; Peter Thompson; Lindsay Billingsley; et al. (Psychedelic Medicine, 2026)

Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols - Damian Świeczkowski; Aleksander Kwaśny; Krzysztof Sadko; Wiesław Jerzy Cubała (European Neuropsychopharmacology, 2026)

Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST (PsyArXiv, 2026)

Psilocybin rapidly, but not immediately, reverses reward learning deficits in a durable manner in an inflammatory rat model of depressive symptoms - Hinchcliffe JK; Thomas CW; Gilmour G; Robinson ES. (bioRxiv, 2026)

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial (PsyArXiv, 2026)

The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise? - Celia Faye Jacobsen; Dea Siggaard Stenbæk; Stig Poulsen; Sophia Armand (Psychiatric Research and Clinical Practice, 2026)

Intentions, Spirituality, Set, and Setting Are Associated with Mystical Experiences in Psilocybin-Assisted Therapy - Kelsey T. Laird; Prabha Siddarth; Ashley Ramos; Rhianna Rich; Brittany Youssef; Grace M. Schwartz; Karina Sergi; Micah Linton; L. Schwartzberg; Daniel F. Kelly; Keith G. Heinzerling (Psychedelic Medicine, 2026)

A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2026)

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis - Johns Hopkins University (ClinicalTrials.gov, 2026)

Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain - University of California; San Diego (ClinicalTrials.gov, 2026)

Sense-making around psilocybin in UK women experiencing cancer-related existential distress: An Interpretative Phenomenological Analysis - Zaynab Khan; Sterre Weaver; Rachael V. Dando; Anne Katrin Schlag; Joanna; id_orcid 0000-0002-2717-9739 Neill; Verity; id_orcid 0000-0002-9876-250X Wainwright (Research Explorer (The University of Manchester), 2026)

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons - Koch P; Schmidt M; Hoffrichter A; Davoudi M; Horschitz S; Lau T; Meinhardt M; Spanagel R; Ladewig J; Köhr G. (Research Square, 2026)

Presence of 4-Hydroxy-N-methyl-N-ethyltryptamine in Commercially Available Products. - Barovic A; Pittiglio MK; Barrett JM; Aretz CDJ; Tesfatsion TT; Ramirez GA; Cruces W. (2026)

Psilocybin shapes neural plasticity in selective brain networks - Sian Lewis (Nature reviews. Neuroscience, 2026)

The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior - Zuzanna Kościuk; Izabela Szpręgiel; Agnieszka Bysiek; K. Gołembiowska (Pharmacological Reports, 2026)

Psilocybin and Bipolar Depression: Promise and Prudence - Matheus G. Marques; Liliana Patarroyo-Rodríguez; Balwinder Singh (CNS Drugs, 2026)

An open-label pilot study of psilocybin-assisted therapy for binge eating disorder - Jesse Dallery; Jennifer L. Miller; Jeff Boissoneault; Lauren Harvey; Lindsey Ives; Alexandra Knerr; Shelby Blaes; Morgan N. Ransom; Melissa S. Munson; James P. Gilligan; Michael H. Silverman; Peter R. Guzzo; et al. (Journal of Eating Disorders, 2026)

The one that abstained: Psilocybe fuscofulva genome suggests two recent origins of the psilocybin gene cluster in Psilocybe - Slot J; Bradshaw A; Dentinger B; Borovička J; Konkel Z; Rockefeller A; Bollinger I. (bioRxiv, 2026)

Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress - Frederick D. Sancilio; Maghsoud Dariani; Purvi Chavda; Harsha Mysore Rajagopal; Lyl Tomlinson (Journal of Psychoactive Drugs, 2026)

The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis - Reza Moshfeghinia; Sara Mostafavi; Kimia Jazi; Amir Reza Ghasemi; Yasamin Khosravaninezhad; Santhosshi Narayanan; Jamshid Ahmadi; Mehdi Pasalar (BMC Psychology, 2026)

Motivation-based subtypes of psilocybin microdosers - Ethan Klukas (Open Collections, 2025)

COMBINATION OF PSILOCYBIN AND COGNITIVE BEHAVIORAL THERAPY IMPROVES OXYTOCIN LEVELS AND DEPRESSIVE SYMPTOMS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER - Mahvash Khan; Muhammad Omar Malik; Sara Sajjad; Muhammad Uzair; Inayat Shah; Muhammad Ismail Bhatti (Genetics and Molecular Research, 2025)

Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic Review - Marta Gómez Álvarez; Javier Calleja-Conde; Víctor Echeverry-Alzate (Open Science Framework, 2025)

Symptom-level antidepressant response to psilocybin: exploratory outcomes comparing psilocybin treatment to niacin - E. Lopez; J O Lundberg; F. Hieronymus; M. Beckman; H. Yngwe; C.J. Ekman; M. Tiger; N. Edvall (Neuroscience Applied, 2025)

Self-reported benefits and harms of microdosing with natural psilocybin: preliminary results from a naturalistic study - I. Totomanova; E.C.H.M. Haijen; P.P.M. Hurks; NL Mason; JG Ramaekers; K.P.C. Kuypers (Neuroscience Applied, 2025)

Dynamic response of intrinsic connectivity networks to low-dose psilocybin during face matching in autistic adults - Y. Ge; T.P. Whelan; M. Dimitrov; C.L. Ellis; F. Moruzzi; J. Kangas; F.M. Ponteduro; N. Khalil; S. Fenn-Moltu; NA Puts; E. Daly; D.G.M. Murphy; et al. (Neuroscience Applied, 2025)

Cost-Effectiveness of Psilocybin-Assisted Therapy (PAT) for Patients with Treatment-Resistant Depression - Yosr Ziadi; Taehwan Park (Open MIND, 2025)

Psilocybin-Assisted Therapy for Mood Disorders: A Comparative Literature Review of Australia, the United States, the United Kingdom, and Canada - Jorge Oliveira (2025)

Optimization of Psilocybin Extraction from Psilocybe cubensis Mushrooms and Characterization of the Fungal Extract - Mateus Araújo da Luz; Taynah Pereira Galdino; Lucas Matheus da S. Oliveira; H. Guedes; Anauara Silva; Victor I. Afonso; Suédina M. L. Silva; Antônio G. B. Lima; Marcus V. L. Fook; Maria C. M. Torres (Journal of the Brazilian Chemical Society, 2025)

Additional file 1 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorder - Jesse Dallery; Jennifer L. Miller; Jeff Boissoneault; Lauren Harvey; Lindsey Ives; Alexandra Knerr; Shelby Blaes; Morgan N. Ransom; Melissa S. Munson; James P. Gilligan; Michael H. Silverman; Peter R. Guzzo; et al. (Figshare, 2025)

Additional file 2 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorder - Jesse Dallery; Jennifer L. Miller; Jeff Boissoneault; Lauren Harvey; Lindsey Ives; Alexandra Knerr; Shelby Blaes; Morgan N. Ransom; Melissa S. Munson; James P. Gilligan; Michael H. Silverman; Peter R. Guzzo; et al. (Figshare, 2025)

Facing Mortality Together: A Constructivist Grounded Theory Analysis of Group Psilocybin Therapy Among Older Long-Term AIDS Survivor Gay Men - Hannah Whitmore; Maria Mangini; Heather Leutwyler; Brian Anderson (Palliative Medicine Reports, 2025)

Psilocybin-Therapie vorteilhaft für Stimmungsstörungen von Parkinsonkranken (Fortschritte der Neurologie · Psychiatrie, 2025)

‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injury - Maurice Lam; C. Khor; S. Hultin; J. J. Cheung; N. A. Shah (Internal Medicine Journal, 2025)

Electrical brain changes following psilocybin administration in sprague-dawley rats - B. Richardson; V. Bruno; J. O'Byrne; G. Gobbi (Neuroscience Applied, 2025)

Low dose psilocybin differentially alters resting-state network connectivity in autistic and non-autistic people - T. Whelan; M. Dimitrov; C.L. Ellis; F. Moruzzi; J. Kangas; N. Khalil; G. Ivin; E. Daly; NA Puts; D.G.M. Murphy; G.M. McAlonan (Neuroscience Applied, 2025)

Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial - L.J. Mertens; M. Koslowski; F. Betzler; M. Brand; R. Evens; L. Krätner; A. Jungaberle; H. Jungaberle; T. Majić; C.N. Schmitz; A. Ströhle; D. Scharf; et al. (Neuroscience Applied, 2025)

The impact of COMP360 psilocybin on anhedonia: post-hoc analyses from a phase IIb randomised controlled trial - L. Marwood; M. Young; J. Chai-Rees; S. Mistry; S. Maxwell; G.M. Goodwin (Neuroscience Applied, 2025)

Psilocybin and ibogaine as therapeutic candidates for cocaine addiction: Insights from a rat self-administration model - I.R.A. Koutrouli; K. Šíchová; W. Kacper; V. Brejtr; K. Aleksič; N. Miniariková; E. Lhotková; M. Nikolič; T. Páleníček (Neuroscience Applied, 2025)

An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes - N. Mcgowan; J. Rucker; R. Yehuda; M. Agrawal; H. Simmons; S. Das; G. Goodwin (Neuroscience Applied, 2025)

Relationship between cardiovascular effects and psychedelic experiences under psilocybin in patients with treatment-resistant depression - L. Puhl; L. Kunz; M. Berger; G. Gründer; L. Mertens; M. Spangemacher (Neuroscience Applied, 2025)

Psilocybin Treatment for Refractory Depression: A Clinical Review - Jensen; Hailey A (Digital Commons - Gardner-Webb University (Gardner-Webb University), 2025)

The impact of drug control on wider research: Psychedelic mushroom exploration - Sam Lasham; Rhys Ponton (Drug Science Policy and Law, 2025)

Preclinical evaluation of psilocybin as an anti-inflammatory agent - N. Martínez-Álvarez; I. Erkizia-Santamaría; A. Tomás-Alvarado; A.M. Erdozain; J.J. Meana; J.E. Ortega (Neuroscience Applied, 2025)

Psilocybin increases connectivity between unimodal and transmodal networks in healthy volunteers listening to music - M. Benes; D. Gregus; P. Adamek; T. Páleníček; J. Horacek (Neuroscience Applied, 2025)

Effects of low-dose psilocybin on EEG markers of sensory processing in autistic and non-autistic adults - O. Ollari; T.P. Whelan; C.L. Ellis; N. Khalil; F. Moruzzi; D.G.M. Murphy; E. Daly; L. Mason; N. Puts; G.M. McAlonan (Neuroscience Applied, 2025)

Mismatch between psilocybin-induced head-twitch behaviour and psilocin brain levels in mice - F. Sellitti; C. Weber; É. Tamura; Z. Li; J. Thomann; D. Luethi; L.D. Simmler (Neuroscience Applied, 2025)

Preliminary results from an ongoing naturalistic survey study investigating dose-finding practices and effects of self-administered small amounts of psilocybin - I. Totomanova; E.C.H.M. Haijen; Petra P. M. Hurks; NL Mason; K.P.C. Kuypers (Neuroscience Applied, 2025)

Temporal effects of a single oral dose of psilocybin on plasma circulating miRNAs in humans - A. O'shea; JG Ramaekers; R. Schreiber; J.J. Briedé; J. Krauskopf; N. Mason; M.C.T. Verheijen (Neuroscience Applied, 2025)

Behavioral and neuronal effects of psilocybin in mice - C. Weber; F. Sellitti; L. Ziming; J. von Arx; L.D. Simmler (Neuroscience Applied, 2025)

Psilocybin: clinical potential, mechanistic insights, and biotechnological advances for scalable production - Islas-Vargas J; Armenta S; Rivera-Román ÁA; Hernández-León S; Méndez-Hernández JE; Arce-Cervantes O. (2025)

Toxicology and Pharmacological Interactions of Classic Psychedelics. - Thomas K. (2025)

Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms. - Holze F; Liechti ME; Müller F. (2025)

Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review. - Viljoen G; Betzler F (Current topics in behavioral neurosciences, 2025)

Informed Consent in Psychedelic-Assisted Therapy. - Bradberry MM; Appelbaum PS; Gukasyan N. (2025)

Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability. - Chwyl C; Wilson-Poe AR; Hoffman KA; Bazinet A; Pertl K; Luoma JB; des Jarlais D; Bielavitz S; Korthuis PT (The International journal on drug policy, 2025)

Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics. - Hirschfeld T; Blei F; Stegemann L; van der Gouwe D; Smit-Rigter L. (2025)

Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation - Philip Kamilar-Britt; Alyssa B. Oliva; Mitch Earleywine (Journal of Psychoactive Drugs, 2025)

An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in mice - Connor J. Maltby; Adam K. Klein; Enya Paschen; Jessica Pinto; Dino Dvořák; Joseph R. Hedde; Ashley N. Hanks; Massimiliano Bianchi; Zoe Hughes (Journal of Psychopharmacology, 2025)

The Effect of Magic Mushroom ( Psilocybe azurescens ) on Social Interaction, Anxiety- and Depressive-Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors - Hediye Moghadam; Parisa Akbari; Elmira Beirami; Samaneh Nabavifard; Akram Ameli; Neda Valian (Journal of Neuroscience Research, 2025)

Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin - Brunno Freitas da Costa; Paula Hartmann; Daniel Pagnin (Human Psychopharmacology Clinical and Experimental, 2025)

Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex - Ziran Huang; Xiaoyan Wei; Yihui Wang; Jin Tian; Jihui Dong; Bo Liang; Lin Lu; Wen Zhang (Neurotherapeutics, 2025)

Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy. - Bröcker AL; Majić T; Montag C. (2025)

Classifying Psychedelic-Related Complications. - Majić T; Gouzoulis-Mayfrank E; Evens R. (2025)

New Antidepressant Development in the Treatment of Depression. - Spiti A; Caldirola D; Perna G. (2025)

Psychedelics: Future Therapeutics in Major Depression? - Olivier B; Olivier JDA. (2025)

Neuroscience: What doesn't kill you makes you stronger. - Kucukdereli H; Douglass AM. (2025)

[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges]. - Xia K; Gao T. (2025)

Psychedelic therapy and postpartum depression: priorities and prospects. - Thuery G; Crossen F; Mc Loone D; Hinds C; Duffy R; Jairaj C; Harkin A; Kelly JR (Therapeutic advances in psychopharmacology, 2025)

Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat - Ashkan Veysi; Daniela Atanasovski; Maryam Ardalan; Nasrin Motamed; Elias Eriksson (Acta Neuropsychiatrica, 2025)

Correction: Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021. - Abramsky-Sze S; Marseille E; Matzopoulos R; Morlock R; Lerer L (Frontiers in psychiatry, 2025)

The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures - Petr Scholle; Štěpán Wenke; Tereza Nekovářová; Yulia Zaytseva; Filip Tylš; Martin Brunovský; Jiřı́ Horáček; Veronika Andrashko; Vlastimil Koudelka; Michaela Viktorinová; Vojtěch Viktorin; Kateřina Hájková; et al. (Journal of Psychopharmacology, 2025)

Self-Transcendent Perceptual Dynamics and the Effects of Dispositional Mindfulness on Altered States of Consciousness: A Prospective Longitudinal Observational Study of a Naturalistic Psychedelic Retreat (PsyArXiv, 2025)

A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial - University of Calgary (ClinicalTrials.gov, 2025)

Microdosing Psychedelics to Improve Mood - Rotem Petranker (ClinicalTrials.gov, 2025)

Distinguishing 4- vs 5-Hydroxy-N,N-Dimethyltryptamine (Psilocin vs Bufotenine) Using Hydrogen-Deuterium Back-Exchange. - Christopher MW; Prentice BM; Garrett TJ. (2025)

Psilocybin Production With Genetically Modified Aspergillus nidulans Under Pressurized Conditions - Sophie Weiser; Sidney Jung; Bettina Bardl; Johann E. Kufs; Slavica Janevska; Vito Valiante; Dirk Hoffmeister; Lars Regestein (Biotechnology and Bioengineering, 2025)

Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes - Yale University (ClinicalTrials.gov, 2025)

Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks - Miguel Benjamín Cervera-Sánchez; Daniel San-Juan; Roberto Díaz-Peregrino; Evelin Zulema Camacho-Castillo; Sthefany Anahi Bringas-Ortiz; Christian Padilla-Cabezutd (2025)

Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial - Emmanuelle A. D. Schindler; Christopher Gottschalk; Brian Pittman; Deepak D'Souza (Headache The Journal of Head and Face Pain, 2025)

A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder - Rhianna Rich; Kelsey T. Laird; Prabha Siddarth; Brittany Youssef; Grace M. Schwartz; Ashley Ramos; Karina Sergi; Micah Linton; L. Schwartzberg; Daniel F. Kelly; Keith G. Heinzerling (Psychedelic Medicine, 2025)

Psilocybin decreases reward-seeking behavior accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex - Houff J; Williams A; Allen O; Gisabella B; Pantazopoulos H; Del Arco A. (bioRxiv, 2025)

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research. - Stocker K; Hartmann M; Schmid Y; Vogt SB; Becker AM; Ley L; Straumann I; Arikci D; Klaiber A; Erne L; Vizeli P; Holze F; et al. (2025)

Evolution and horizontal transfer of the psilocybin biosynthetic gene cluster drive the diversification of magic mushrooms - Fei Liu; Jiaxin Li; Wen-Qiang Yang; Mao-Qiang He; Bin Cao; Qi Wu; R. Cheewangkoon; Rui-Lin Zhao (Mycosphere, 2025)

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation - Sheppard Pratt Health System (ClinicalTrials.gov, 2025)

An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder - University of Chicago (ClinicalTrials.gov, 2025)

A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants - Bhagavan C; Carter O; Nielsen G; Berlowitz D; Issak S; Braat S; Zaloumis S; Attard Z; Oliver G; Mayne D; Rucker J; Butler M; et al. (medRxiv, 2025)

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study - Anthony L. Back; Bonnie A. McGregor; Lindsay Billingsley; Dianna Blom; George Callan; Susanna Myers; John Guy; Sameet Kumar; Melissa Layer; Jackie Levin; Juliana Pérez; Peter Thompson; et al. (Psychedelic Medicine, 2025)

The genus Psilocybe in Italy - Giuseppe Venturella; Manuela Rollini; Giulia Mirabile; Nicola Favia; Maria Letizia Gargano (Italian Botanist, 2025)

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter - NYU Langone Health (ClinicalTrials.gov, 2025)

Psilocybin modulates social behaviour in male and female mice in a time-dependent manner - Shadani S; McCoy K; Ong L; Greaves E; Conn K; Andrews ZB; Foldi CJ. (bioRxiv, 2025)

A Naturalistic Study on the Combined Neural and Psychological Effects of Psilocybin and Compassion Focused Imagery - Pallavicini C; Llobenes L; Cavanna F; de la Fuente LA; Muller S; Costa M; Gumiy N; Bruno N; D’Amelio T; Basran J; Plowright P; Stolkiner A; et al. (bioRxiv, 2025)

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder - Jonathan Brett; Toby Lea; Elizabeth Knock; Steven M. Albert; Liam Acheson; Krista J. Siefried; Sebastian Job (Addiction, 2025)

The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview. - Carlson LE; Richardson H; Shore R; Albertyn CP; Balneaves LG; Bates A; Burnell M; Chochinov HM; Clements D; Deleemans J; Horlock H; Mathews J; et al. (Current oncology (Toronto, Ont.), 2025)

Magic mushrooms and mood: exploring Psilocybin as a depression treatment - M. Haseeb Ul Rasool; Taha Hannan; Muhammad Imam (Journal of the Pakistan Medical Association, 2025)

Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research - Amanda Husein; Madalynn Traylor; M. Frances Vest; Bo Jarrett Wood; Madison Brogan; Alfred Thomas; Shawn E. McNeil; M Alfrad Nobel Bhuiyan; Peter S. Hendricks; John R. Kelly; Andrew Gribben; Sultan Alqahtani; et al. (Psychedelic Medicine, 2025)

From fungi to pharmacy: Applied technologies in psilocybin production and its therapeutic applications - Qinqing Chen; Peiyuan Chen; Tao Wei; Sunita Chamyuang; Bai-Xiong Chen (Creative Science, 2025)

Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study - Mylène Cheng; Tatiana Aboulafia Brakha; Albert Buchard; Raya Anastasova; Léa Girani; Anna Breitenmoser; Sylvie Alaux; Cédric Mabilais; Caroline Amberger; Federico Seragnoli; Leonice Furtado; Gabriel Thorens; et al. (Psychology International, 2025)

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder - NYU Langone Health (ClinicalTrials.gov, 2025)

Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development - Koning E; Gamberg S; Keshen A. (Preprints.org, 2025)

Wherefore the magic? The evolutionary role of psilocybin in nature - Matthews Nicholass K; Flis I; Hanley M; Knight M; Lane S; Littlejohn G; Thom M; Billington R; Boden R; Cummins R; Green B; Griffin C; et al. (bioRxiv, 2025)

A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2025)

Psilocybin reporting in media (PRiMe) for the treatment of depression - Gurjot Brar; T. R. JUN. BURKE; Andrew Gribben; Colm Harrington; Guillaume Thuery; John R. Kelly (Irish Journal of Psychological Medicine, 2025)

Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy. - Matos ARS; Silva AC; Rego L; Fernandes R; Gonçalves S. (2025)

Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders (PsyArXiv, 2025)

Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape - Megan Dutton; Paul Schwenn; Jules Mitchell; Per Hoffmann; Neil W. Bailey; Paul B. Fitzgerald; Jim Lagopoulos; Adem Can (Australian & New Zealand Journal of Psychiatry, 2025)

Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy - Faheem Ahmed Khan; Nuruliarizki Shinta Pandupuspitasari; Tewin Tencomnao; Siriporn Chuchawankul (Journal of Affective Disorders, 2025)

Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats - Sophie Woodruff; Meghan Hibicke; Charles D. Nichols (Psychedelic Medicine, 2025)

Exploring Determinants of Psilocybin Acceptance as an Alternative Modality for Major Depressive Disorder: A Pilot Study - Shannon Antoine-Hardy; D’Elia Bonilla (Journal of Complementary and Alternative Medical Research, 2025)

Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer - Yvan Beaussant; MD; MSci (ClinicalTrials.gov, 2025)

Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine-DMT Formulations - Anna C. Renner; Robert B. Kargbo (ACS Medicinal Chemistry Letters, 2025)

Psychedelic experiences elicited by serotonergic psychedelics: Molecular mechanisms and functional connectivity changes in the brain. - Vollebregt R; Storm AEM; Lucassen PJ; Somers M. (2025)

Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study - Nicole Ledwos; Jenna Baer; Muhammad Ishrat Husain; Daniel M. Blumberger; Rachel Patterson; Elizabeth Hollingdrake; Ezmond S.L. Cheung; Colin Hawco; Christoph Zrenner; Brigitte Zrenner; Jamie D. Feusner; Susan L. Rossell; et al. (BJPsych Open, 2025)

The entropic brain today - Carhart-Harris R. (PsyArXiv, 2025)

The entropic brain today (PsyArXiv, 2025)

COMPARATIVE EFFICACY AND ACCEPTABILITY OF PSILOCYBIN-KETAMINE AND TYPICAL ANTIDEPRESSANTS FOR MAJOR DEPRESSIVE DISORDER MANAGEMENT: A NETWORK META-ANALYSIS - Pedro Rodrigues; Weliton Rodrigues dos Santos Júnior; Ivan de Sousa Araújo; Leonardo Maia Leony; Fernanda Adélia Almeida Custódio Pires Gomes; Tairone Matos de Lima Junior; Luís Felipe Freitas Moreira; Rafael Telles Santana; Manoel Carlos Matos Santos; R. Silva (2025)

Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency - Samuel Hosford; Heather Austin-Robillard (Contemporary Family Therapy, 2025)

Age and cannabis co-use are associated with differences in experience and perceived benefits of psilocybin: a retrospective study (PsyArXiv, 2025)

Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study - Jungwirth J; Westenhöfer S; Aicher H; Provaznikova B; Kronenberg G; Seifritz E; Prinz S; Olbrich S. (Research Square, 2025)

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis - T. H. W. Ching; B. Stahnke; S. Shnayder; G. Agin-Liebes; T. G. Adams; L. Amoroso; O. Baiz; A. Belser; C. Bohner; M. Burke; E. D’Amico; G. DePalmer; et al. (Frontiers in Psychiatry, 2025)

Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review - Suspène J; Huet S; Berteina-Raboin S; Benyamina A; Baril P; Morisset-Lopez S; Serreau R. (Qeios, 2025)

Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety - Gerasimos Konstantinou; Joshua D. Rosenblat; Sarah Hales; Muhammad Ishrat Husain; Daniel M. Blumberger (General Hospital Psychiatry, 2025)

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience - Namik Kirlić; Merve Atli; Sunil Mistry; Michael Gold; Guy M. Goodwin (Journal of Clinical Psychopharmacology, 2025)

Are Magic Mushrooms the Magic to Healing? - Wohlfarth; Gale; Hardy; Susan; Ray; Herman (DigitalCommons - Kennesaw State University (Kennesaw State University), 2025)

Unlocking the power of tryptamine alkaloids in Psilocybe fungi: chemistry, mental health potential and legal challenges - Mohammad Reza Mirzadeh; Khalid Moinuddin; Vasso Apostolopoulos; Caine Barlow; Jianhua Zhang (Mycological Progress, 2025)

Disengaged: A systematic review of community engagement in psychedelic-assisted therapy research. - Reid MR; Song J; Boehnke KF; Buchanan NT; Aday JS. (2025)

The effect of dextromethorphan on reward-related behaviors: A systematic review of preclinical and clinical evidence. - Teopiz KM; Le GH; Wong S; McIntyre RS. (2025)

Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study - Imperial College London (ClinicalTrials.gov, 2025)

Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study - University of British Columbia (ClinicalTrials.gov, 2025)

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer - NYU Langone Health (ClinicalTrials.gov, 2025)

Defining ‘psychedelic’ (PsyArXiv, 2025)

Questioning the recovery of dissociated traumatic memories under psilocybin: comment on “Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa” - Samuli Kangaslampi; Max Wolff; Manoj K. Doss; Lilian Kloft; Henry Otgaar (Journal of Eating Disorders, 2025)

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine. - Dodds C; Dawson R; Lim A; Tye S; Nasrallah F. (2025)

Comment on: Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis. - Machado T; Rodrigues ASL; Costa J. (2025)

Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears - Spohn; Kyle (eYLS (Yale Law School), 2025)

Efficacy of psilocybin on death anxiety in terminal patients: a narrative review - Morris Lintong Barimbing; Dian Pritasari Jeger; Made Edwin Sridana (Progress in Palliative Care, 2025)

Unexpected Detection of Psilocybin in a 100 mg Tramadol Tablet: A Forensic Case Report - Amin Reihani; Fatemeh Shaki (DOAJ (DOAJ: Directory of Open Access Journals), 2025)

Psilocybin and Neuroplasticity: Mechanisms, Therapeutic Potential, and Future Directions - S. Fereydouni (Emerging Trends in Drugs Addictions and Health, 2025)

Taking a Trip into Nature’s Medicine Cabinet: A Country Comparison of Efforts to Reschedule Psilocybin and MDMA for Therapeutic Use - Jones; Ariyah (eYLS (Yale Law School), 2025)

Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen - Wopfner; Alexander; Soravia; Leila M. (Open Access CRIS of the University of Bern, 2025)

Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients - Philip Garrity; Alicia Danforth; Brian Anderson; Jason M. Thompson (Journal of Health Service Psychology, 2025)

Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study - Bukovsky D; Amaev A; Song J; Torres-Carmona E; Kyte S; Ueno F; Deluca V; Bowie C; Flint A; Husain I; Graff-Guerrero A; Gerretsen P. (2025)

Psilocybin Maintains Better Brain Function in an Alzheimer’s Disease Model with Reduced Neuroinflammation and Improved Hippocampal Neurogenesis - Madhu L; Somayaji Y; Kotian S; Attaluri S; Patel J; Panda P; Rao V; Kodali M; Shankar G; Rao S; Weintraub S; Shuai B; et al. (2025)

Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement - Buchard A; Seragnoli F; Sabe M; Eskinazi M; Aboulafia T; Furtado L; Briefer J; Roediger E; Penzenstadler L; Zullino D; Thorens G. (Research Square, 2025)

Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland - Aboulafia-Brakha T; Buchard A; Mabilais C; Alaux S; Amberger C; Furtado L; Seragnoli F; Briefer J; Thorens G; Sabé M; Szczesniak L; Iuga R; et al. (medRxiv, 2025)

Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin. - Purple RJ; Gupta R; Thomas CW; Golden CT; Palomero-Gallagher N; Carhart-Harris R; Froudist-Walsh S; Jones MW. (2025)

Sudden Loss of Consciousness Following Psilocybin Ingestion - Amanda E. Downey; Marlene Tai; Ellen Bradley; Josh Woolley (American Journal of Psychiatry, 2025)

Acute Blockade of the Serotonin Transporter With Low Doses of Escitalopram Does Not Alter the Behavioural Responses to Acute Psilocybin - Nina Kleditzsch; James J Gattuso; Anthony J. Hannan; Thibault Renoir (European Journal of Neuroscience, 2025)

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment - Nadav Liam Modlin; Victoria Williamson; Guy M. Goodwin; Ekaterina Malievskaia; Merve Atli; Zsofia Elek; Alice Gaillard; Don Koelpin; Anthony J. Cleare; Manish Agrawal; Rachel Yehuda; Namik Kirlić; et al. (EClinicalMedicine, 2025)

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions: The Great Promise of Psychedelics: Evolving Human Consciousness - Tara Brach (Psychedelic Medicine, 2025)

Griffiths et al.’s Study of Psilocybin with Religious Professionals: A Theological Response from a Christian Perspective - Joseph G. Lorenz; Scott A. Hawkins; Bryan C. McCarthy (Psychedelic Medicine, 2025)

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions, by Griffiths et al - Harriet de Wit (Psychedelic Medicine, 2025)

Psilocybin, Spirituality, and the Potential for Personal Transformation: Commentary on Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions by Griffiths et al - Kenneth I. Pargäment (Psychedelic Medicine, 2025)

Psilocybin vs Ketamine for Alcohol Use Disorder - University of Iowa (ClinicalTrials.gov, 2025)

Using Insights from a Study of Psilocybin with Clergy to Advance Research on Psychedelics, Spirituality, and the Sacred: Commentary on Griffiths et al. (2025) - Roman Palitsky; George H. Grant (Psychedelic Medicine, 2025)

Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers. - University College; London (ClinicalTrials.gov, 2025)

Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder - University of Texas at Austin (ClinicalTrials.gov, 2025)

A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model - Małgorzata Domżalska; Joanna Kwiatkowska; Iwona Cichoń; Ewa Sokołowska (Scientific Reports, 2025)

Psilocybin reduces comorbid chronic pain and depression in mice - Jorge Ferreira (Lab Animal, 2025)

New treatments for OCD? Evidence for cannabinoids and psychedelics. - Van Ameringen M; Patel V; Patterson B; Hopkinson P; Rahat M. (2025)

Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life - Charles S. Grob; M.D. (ClinicalTrials.gov, 2025)

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Disorders: A Scoping Review - J Pincombe; M.L. Williams; Sean Carruthers; Susan L. Rossell (Psychedelic Medicine, 2025)

Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder - Sana Rasheed; Rida Arif; Ahmed Asad Raza; Abedin Samadi (Annals of Medicine and Surgery, 2025)

Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial - Danica E. Johnson; Shakila Meshkat; Erica Kaczmarek; Jennifer S. Rabin; Ryan M. Brudner; Noah Chisamore; Zoe Doyle; Jordan Bawks; Jeremy Riva-Cambrin; Rodrigo B. Mansur; Orly Lipsitz; Roger S McIntyre; et al. (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2025)

Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports - Holly Hepburn; Bart Ellenbroek; Jiun Youn (Psychedelics, 2025)

Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward - Alaina M. Jaster; Thomas M Hadlock; Belle Buzzi; Jessica L. Maltman; Gabriella Silva; Somdatta Saha; Eda Köşeli; Abby M Pondelick; Nikita Thakur; Xin Zhang; Gaoshan Li; Sandra Ledesma-Corvi; et al. (Nature Communications, 2025)

Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists? - Silvia Natoli; Arturo Cuomo; Maurizio Marchesini; Livio Luongo; Giuliano Lo Bianco; Vittorio Guardamagna; Shigeki Yamaguchi (Medical Sciences, 2025)

Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans - University of Zurich (ClinicalTrials.gov, 2025)

A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression - Beersheva Mental Health Center (ClinicalTrials.gov, 2025)